Saha Srishti, Khanna Sahil
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Therap Adv Gastroenterol. 2019 May 6;12:1756284819847651. doi: 10.1177/1756284819847651. eCollection 2019.
infection (CDI) is a common cause of diarrhea in both inpatient and outpatient settings. The last few years have seen major changes in the treatment spectrum of CDI, most notably, recommendations against using metronidazole for initial CDI, the addition of fidaxomicin and bezlotoxumab, and emergence of microbial replacement therapies. Several other therapies are undergoing clinical trials. This narrative review focuses on the treatment of CDI with a summary of literature on the newer modalities and the treatment guidelines issued by Infectious Diseases Society of America and European Society of Clinical Microbiology and Infectious Diseases.
艰难梭菌感染(CDI)是住院患者和门诊患者腹泻的常见原因。在过去几年中,CDI的治疗领域发生了重大变化,最显著的是,不建议使用甲硝唑治疗初发CDI、添加非达霉素和贝佐妥单抗,以及微生物替代疗法的出现。其他几种疗法正在进行临床试验。这篇叙述性综述重点关注CDI的治疗,总结了关于新疗法的文献以及美国传染病学会和欧洲临床微生物学与传染病学会发布的治疗指南。